Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: February 14, 2018
Context: The Company filed a "Kessan Tanshin" report with the Tokyo Stock Exchange containing financial results for the year ended December 31, 2017, and a financial forecast for 2018. This filing serves as Regulation FD disclosure.
Key Financial Metrics and Guidance
The filing provides a financial forecast for the upcoming periods rather than historical performance data for 2018. The Company expects zero revenue for the forecasted periods.
| Period | Revenues | Operating Loss | Net Loss | Loss Per Share (Basic & Diluted) |
|---|---|---|---|---|
| Interim (6 months ending June 30, 2018) | $0 | $9,341,000 | $9,341,000 | $0.22 |
| Full Year (ending Dec 31, 2018) | $0 | $18,391,000 | $18,391,000 | $0.44 |
Note: Loss per share calculations utilize a weighted average of 42,000,000 shares. The filing does not provide specific historical revenue, cash flow, or debt figures for the 2017 period, referring instead to the Annual Report on Form 10-K.
Material Changes and Prior Period Comparison
The filing text does not provide specific numerical comparisons to the prior comparable period (2017) other than noting the Tanshin is substantially the same as the 2017 Form 10-K. The primary material update is the issuance of the 2018 financial forecast.
Outlook, Risks, and Management Commentary
- Forecast Basis: Estimates are based on management's assumptions regarding current conditions and trends. Independent auditors have not compiled or verified these forecasts.
- Key Risks: The Company highlights significant uncertainties, including the potential for product candidates to fail to receive regulatory approval, delays in clinical trials, inadequate therapeutic efficacy, and the ability to raise sufficient capital.
- Forward-Looking Statements: The report contains numerous forward-looking statements regarding operating strategy, licensing, and market potential, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
- Currency: Supplementary financial statements in Japanese yen were translated at a rate of 108.79 JPY per USD as of January 31, 2018.
Investor Verification Checklist
- Verify the full historical financial results for the year ended December 31, 2017, in the Company's Form 10-K, as this 8-K only provides a forecast.
- Confirm the Company's current cash reserves and liquidity position to assess the ability to fund the projected $18.4 million net loss for 2018.
- Review the status of ongoing clinical trials and regulatory submissions for product candidates, as these are cited as primary risks to the forecast.
- Monitor for any updates on capital raising efforts, given the Company's reliance on external financing to sustain operations.